Abortion with sulprostone, a prostaglandin E2 derivative.

Abstract

Sulprostone, a prostaglandin E2 derivative, was used in a multicenter trial to terminate 478 pregnancies of 8-21 weeks' gestation. The compound was clinically well accepted without premedication in extraovular, intravenous and intramuscular routes of administration. At 24 hours after treatment, 67%-88% of the patients had aborted, with a low average incidence of side effects. Sulprostone is preferred clinically to primary prostaglandins. Intravenous infusion was found to be the safest route, but intramuscular injection proved to be the most practical.

• Authors: M O Pulkkinen, P Kajanoja, A Kivikoski, J Saastamoinen, K Selander, R Tuimala
• Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (Int J Gynaecol Obstet) Vol. 18 Issue 1 Pg. 40-3 ( 1980) ISSN: 0020-7292 [Print] United States
• PMID: 6106599 (Publication Type: Journal Article)

Chemical References

• Abortifacient Agents, Steroidal
• Prostaglandins E

Topics

• Abortifacient Agents, Steroidal (administration & dosage, adverse effects, pharmacology)
• Female
• Humans
• Infusions, Parenteral
• Injections, Intramuscular
• Pregnancy
• Prostaglandins E (administration & dosage, adverse effects)